Agios Pharmaceuticals, Inc.

Agios Reports Third Quarter 2026 Financial Results and Provides Business Update

•Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9…